ALFA Finder| Revenue growth | 22% YoY, 7% QoQ. |
|---|---|
| Margins | EBITDA margin at 22.2%, up from 20.2% YoY. |
| Demand visibility | Driven by Finished Dosage segment in US and Europe. |
Growth
Revenue grew 22% YoY and 7% QoQ. EBITDA increased 34% YoY with margins expanding 196 bps to 22.2%.
Outlook
Focusing on scaling from Integrated to Complex Generics; 130 filed dossiers with 36 awaiting approval; ongoing CAPEX of ₹1,298 Mn.
Risks
EBITDA loss of ₹248 Mn from Ascelis Peptides; rising manpower costs (up 35% YoY).
Last quarter's promises, checked
Delivered
- Guided Europe growth → delivered 81% YoY (= BEAT)
- Guided EBITDA positive Senn post-acquisition → delivered positive Q4 EBITDA (= BEAT)
- Guided FY26 Revenue >₹50,000 Mn → delivered ₹53,656 Mn (= BEAT)
Partly delivered
- Guided Net Debt reduction → delivered ₹4,021 Mn from ₹7,061 Mn (= PARTIAL)
Missed
- Guided FY26 Capex ₹5,700 Mn → delivered ₹5,547 Mn (= MISS)
Earnings Call filed with NSE, NSE: GRANULES. Summary written with AI assistance from the document.
Granules India Ltd: key numbers
- Share price
- ₹799.25
- Market cap
- ₹19,805 Cr
- Revenue (annual)
- ₹5,366 Cr
- Net profit (annual)
- ₹595.0 Cr
- P/E (TTM)
- 27.8×Sector 43.8×
- Promoter holding
- 37.39%-0.63% QoQ
- FII holding
- 20.25%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Granules India Ltd
All →Granules India Earnings Call Transcript: Key Takeaways
Q2 revenue ₹1,560 Cr (+20% YoY) and PAT ₹182 Cr (+39%), but EBITDA margin fell 131bps QoQ on West Asia costs. Gagilapur FDA observations leave the warning letter unresolved.
Granules India Other Announcement
Granules India submitted its monitoring agency report on preferential issue proceeds for quarter ended September 2026. It reports no deviation from stated objects.
Granules India Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹15,600 Mn (+20% YoY), EBITDA ₹3,376 Mn (21.6% margin), PAT ₹1,818 Mn (+39%). Net cash ₹8,280 Mn after warrant proceeds.
Granules India Results Update
Granules India reported Q2FY27 revenue of INR 15,600 Mn, up 20% YoY, and PAT of INR 1,818 Mn, up 39%. The company also cited a net cash position and a US FDA audit at its Gagillapur site.
Granules India Q2 FY27 Results: Net Profit ₹181.8 Cr, Up 39.2% YoY
Granules India Ltd reported revenue from operations of ₹1,560 Cr (+20.3% YoY) and net profit of ₹181.8 Cr (+39.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹181.8 Cr · +39.2% YoY
Granules India Business Update
Granules' Gagillapur facility received eleven USFDA observations with no impact on product supply. The inspection was the first since a February 2025 Warning Letter.